Blood· 2018Q1

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Courtney D. DiNardo, Keith W. Pratz, Vinod Pullarkat, Brian A. Jonas et al.

1,862citations
Q1SCImago
2018year

Short summary

A combination of venetoclax with decitabine or azacitidine achieved a 67% complete remission (CR) + CR with incomplete count recovery (CRi) rate in treatment-naive, elderly acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hematology

HematologyMedicine